-
Leerink: Armo Biosciences' 'Promising' Data Justifies A Bullish Stance
Tuesday, March 27, 2018 - 12:24pm | 457ARMO Biosciences Inc (NASDAQ: ARMO)'s lead product candidate AM0010 is a drug for the treatment of pancreatic ductal adenocarcinoma recently showed "promising" data that's supportive of a potentially large commercial opportunity, according to Leerink. The Analyst Leerink's...